ESHG

EUROPEAN SOCIETY OF HUMAN GENETICS

EMPAG

THE EUROPEAN SOCIETY OF HUMAN GENETICS

EUROPEAN HUMAN GENETICS CONFERENCE 2018

in conjunction with the European Meeting on Psychosocial Aspects of Genetics

MiCo | Milan - Italy | June 16 - 19



PROGRAMME

www.eshg.org
facebook.com/eshg.org

@eshgsociety
#eshg2018

COMMITTEES - BOARD - ORGANISATION

European Society of Human Genetics

Executive Board 2017-2018

President
Chrstine Patch, UK

President-Elect
Gunnar Houge, NO

Vice-President
Olaf Riess, DE

Secretary-General
Karin Writzl, SI

Deputy Secretary-General
Carla Oliveira, PT

Treasurer
Andrew Read, UK

Executive Officer
Jerome del Picchia, AT

Scientific Programme Committee

Chair
Joris Veltman, UK

Members
Yasemin Alanay, TR
Alfredo Brusco, IT
Valerie Cormier-Daire, FR
Jose Luis Costa, PT
Domenico Coviello, IT
Yanick Crow, UK
Vita Dolzan, SI
Francesca Forzano, UK
Brunella Franco, IT
Lude Franke, NL
Maurizio Genuardi, IT
Martin Kircher, DE
Maris Laan, EE
Conxi Lazaro, ES
Lucia Migliore, IT
Carla Oliveira, PT
Lucy Raymond, UK
Alexandre Reymond, CH
Samuli Ripatti, FI
Maria Jesus Sobrido, ES
Malte Spielmann, US
Zeynep Tümer, DK
Enza Maria Valente, IT
Thierry Voet, BE
Karin Writzl, SI

EMPAG SPC Co-Chairs

Elisabetta Razzaboni, IT
Sam Riedijk, NL

Annual Meetings Committee 2017-2018

President
Andrew Read, UK

Members
Gunnar Houge, NO
Carla Oliveira, PT
Christine Patch, UK
Olaf Riess, DE
Karin Writzl, SI

Observers
Jerome del Picchia, AT
Jantie de Roos, NL
Kristina Theuerer-Libova, AT
Flora van Laer, NL

Board Members

Kristiina Aittomäki, FI
Marta Bertoli, UK
Olaf Bodamer, US
Isabella Ceccherini, IT
Angus John Clarke, UK
Jill Clayton-Smith, UK
Johan den Dunnen, NL
Munis Dundar, TR
Francesca Forzano, UK
Christian Gilissen, NL
Kinga Hadzsiev, HU
Ellen Heitzer, AT
Robert Hofstra, NL
Bart L. Loeys, BE
Julie McGaughran, AU
Philippos Patsalis, CY
Djana Plaseska-Karanfilska, MK
Trine E. Prescott, NO
Inga Prokopenko, UK
Feliciano Ramos, ES
André Reis, DE
Zeynep Tümer, DK
Hilde Van Esch, BE
Reiner A. Veitia, FR

Liaison Members

Han Brunner, NL
Christophe Cordier, CH
Martina Cornel, NL
Helena Kääriäinen, FI
Thomas Liehr, DE
Milan Macek, CZ
Bela Melegh, HU
Hans Scheffer, NL
Angus Clarke, UK
Gert Jan van Ommen, NL
Joris Veltman, UK

ESHG Office

European Society of Human Genetics
Andrea Robinson
c/o Vienna Medical Academy
Alser Strasse 4, 1090 Vienna, AT
www.eshg.org
T: +43 1 405 13 83 35
F: +43 1 407 82 74
E: office@eshg.org, membership@eshg.org

European Human Genetics Conference 2018

Conference Organisation and Abstract Management

ESHG/EMPAG 2018 Congress Office
Wiener Medizinische Akademie GmbH
Kristina Theuerer-Libova
Alser Strasse 4, 1090 Vienna, AT
T: +43 1 405 13 83 11
F: +43 1 407 82 74
E: conference@eshg.org
www.medacad.org

Exhibition, Sponsoring and Corporate Satellites

ROSE INTERNATIONAL
Exhibition Management and Congress Consultancy bv
Jantie de Roos, Flora van Laer
P.O. Box 93260
2509 AG The Hague, NL
T: +31 70 383 8901
F: +31 70 381 8936
E: eshg@rose-international.com
www.rose-international.com

Hotel Accommodation

MiCo dmc
Ms. Mariarosaria Cavaliere
P.le Carlo Magno 1 - 20149 Milan, IT
T: +39 02 872 550 50
E: ESHG2018.hotel@micodmc.it

ESHG
EMPAG
European Human Genetics Conference
Milan, Italy | June 16-19, 2018
Itinerary

Session P12 - Cancer genetics

P12.176D / D - Diagnostic competence of mir-375 and mir-93-5p serum levels in malignant and non-malignant prostate diseases

June 18, 2018, 4:45 PM - 5:45 PM

Poster Area

Authors

Y. DULGEROGLU[1], **O. EROGLU**[2,3];

[1]Kulu State Hospital, Medical Biochemistry Laboratory, Konya, Turkey, [2]Bilecik Şeyh Edebali University, Faculty of Science and Letters, Department of Molecular Biology and Genetics, Bilecik, Turkey, [3]Bilecik Sehy Edebali University, Biotechnology Research and Application Center, Bilecik, Turkey.

Disclosures

Y. Dulgeroglu: None. **O. Eroglu:** None.

Abstract

Introduction: The study purpose is to examine the diagnostic competence of miR-375 and miR-93-5p serum levels in prostate cancer differential diagnosis. It is also aimed to examine whether there is an interfering situation in the differentiation of chronic prostatitis, benign prostatic hyperplasia (BPH) and prostate cancer, considering the oncogenic and tumor suppressor properties of miRNAs together with the proinflammatory characteristics. **Materials and Methods:** 25 Patients with BPH, 10 patients with chronic prostatitis and 33 patients with prostate cancer were included in the study. RNA isolation, cDNA synthesis and qRT-PCR steps were performed with Qiagen branded kits based on SYBR Green method, using the protocol of the commercial company. For statistical analysis, -ΔCt values, obtained from the use of ce-miR-39 Ct values in normalization, were used. Differences between groups were tested by independent sample t test and variance analysis. ROC analysis was performed to calculate the diagnostic competence. "Fold change" calculations were performed online on Qiagen webpage. In all analyzes, alpha error level was accepted as 0.05. **Results:** The results are summarized in Table-1.**Conclusion:** It was observed that miR-375 and miR-93-5p differ in significantly between malignant and non-malignant disease groups. It was assessed that the sensitivity of miR-375 to differentiate non-malignant diseases from malignant diseases was higher than prostate specific antigen (PSA) and chronic prostatitis may be an interfering condition in BPH and cancer differential diagnosis.

Results

Compared Groups	miRNA	P value	Fold Change	AUC	Specificity	Sensitivity
Malignant-Non-malignant	miR-375	**<0.001**	-4.48	0.781	91%	46%
Malignant-Non-malignant	miR-93-5p	**0.045**	-1.79	0.662	91%	23%
BPH-Chronic prostatitis	miR-375	0.324	-	-	-	-
BPH-Chronic prostatitis	miR-93-5p	0.338	-	-	-	-
BPH-Cancer	miR-375	**<0.001**	-5.60	0.829	91%	56%
BPH-Cancer	miR-93-5p	0.392	-	-	-	-
Chronic prostatitis-cancer	miR-375	0.169	-	-	-	-
Chronic prostatitis-cancer	miR-93-5p	**0.046**	-2.78	0.744	91%	50%